ACM
RVMD icon

Altium Capital Management’s Revolution Medicines RVMD Stock Holding History

Altium Capital Management’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-60,000
Closed -$2.62M – 58
2024
Q4 		$2.62M Buy
+60,000
New +$3.03M 0.74% 45

Other funds holding RVMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Altium Capital Management's RVMD Position: Q1 2025 in Review

Altium Capital Management sold out of Revolution Medicines (RVMD) in Q1 2025, closing a stake of 60,000 shares — an estimated $2.62M sold.

Altium Capital Management first reported a position in RVMD in Q4 2024 and held it in 1 quarter. The position peaked at $2.62M in Q4 2024. 284 funds tracked by Wall St. Rank hold RVMD as of Q1 2025.

  • Altium Capital Management reported no remaining Revolution Medicines position as of Q1 2025 after selling out during the quarter.
  • Altium Capital Management sold 60,000 Revolution Medicines shares in Q1 2025, an estimated $2.62M.
  • Altium Capital Management first reported a position in Revolution Medicines in Q4 2024 and held it in 1 quarter.
  • Altium Capital Management's Revolution Medicines position peaked at $2.62M in Q4 2024.
  • 284 funds tracked by Wall St. Rank held Revolution Medicines as of Q1 2025.

Based on Altium Capital Management's 13F filing for Q1 2025, filed 9 May 2025.